文献速递肾癌与肾肿瘤

肾切除术后肾细胞癌辅助抗血管生成治疗:系统综述与Meta分析

Adjuvant Antiangiogenic Agents in Post-nephrectomy Renal Cell Carcinoma: A Systematic Review and Meta-analysis.
PubMed 文献 · Eur Urol Oncol · 2018-03-15

该系统综述与Meta分析纳入3项RCT共3693例根治性肾切除术后高复发风险的肾细胞癌患者,比较口服抗血管生成药物与安慰剂。汇总结果显示,抗血管生成药物未改善无病生存期(HR 0.92,95%CI 0.78-1.07)和总生存期(HR 0.99,95%CI 0.79-1.25),且与安慰剂相比显著副作用发生率高出2.7倍。

要点

  • 抗血管生成药物未改善肾切除术后高危肾细胞癌患者的DFS和OS。
  • 亚组分析(透明细胞癌、最高复发风险)结果一致,均无获益。
  • 口服抗血管生成药物的显著副作用发生率是安慰剂的2.7倍。

核心结论

  • 在高复发风险的肾切除术后肾细胞癌患者中,抗血管生成药物相比安慰剂未改善总生存期和无病生存期。

研究设计与样本

  • 系统综述与Meta分析,检索PubMed、Embase和Cochrane Central Register of Controlled Trials,纳入评估口服抗血管生成药物对比安慰剂的随机对照试验。
  • 共纳入3项RCT,合计3693例肾切除术后肾细胞癌患者。
  • 采用DerSimonian and Laird随机效应模型汇总效应量。

主要发现

  • 抗血管生成药物未改善无病生存期(HR 0.92,95%CI 0.78-1.07)。
  • 抗血管生成药物未改善总生存期(HR 0.99,95%CI 0.79-1.25)。
  • 限制于透明细胞癌患者和最高复发风险患者时,结果持续。
  • 舒尼替尼在全队列中未改善无病生存期(HR 0.89,95%CI 0.67-1.19)或总生存期(HR 1.11,95%CI 0.90-1.37)。
  • 口服抗血管生成药物的显著副作用发生率比安慰剂高2.7倍。

关键数值与推荐

  • 无病生存期汇总HR 0.92(95%CI 0.78-1.07)。
  • 总生存期汇总HR 0.99(95%CI 0.79-1.25)。
  • 舒尼替尼无病生存期HR 0.89(95%CI 0.67-1.19),总生存期HR 1.11(95%CI 0.90-1.37)。
  • 显著副作用发生率:抗血管生成药物组为安慰剂组的2.7倍。

临床怎么用

  • 目前证据不足以支持在非转移性肾细胞癌肾切除术后使用口服抗血管生成药物。
  • 临床决策时应权衡抗血管生成药物的显著副作用风险(较安慰剂高2.7倍)与缺乏生存获益。

局限性

  • 需要进一步研究以识别可能从辅助抗血管生成治疗中获益的患者人群。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: The role of antiangiogenic agents in advanced renal cell carcinoma (RCC) is well established. However, it is still not clear whether this benefit can be extrapolated to the adjuvant setting. OBJECTIVE: To determine the efficacy and safety of antiangiogenic agents in patients with RCC and a high risk of relapse after nephrectomy. EVIDENCE ACQUISITION: We searched PubMed, Embase, and the Cochrane Central Register of Controlled Trials for randomized controlled trials (RCTs) evaluating the use of any oral antiangiogenic agent compared to placebo in post-nephrectomy RCC patients. Prespecified data elements were extracted from each trial. Outcomes of interest included overall survival (OS) and disease-free survival (DFS). The overall effect was pooled using the DerSimonian and Laird random-effects models. EVIDENCE SYNTHESIS: Three RCTs comparing antiangiogenics to placebo among 3693 patients met our inclusion criteria and were used in meta-analyses. Overall, antiangiogenics did not improve DFS (hazard ratio [HR] 0.92, 95% confidence interval [CI] 0.78-1.07) or OS (HR 0.99, 95% CI 0.79-1.25). These results persisted when restricting the analysis to patients with clear cell carcinoma and patients with highest risk of relapse. Similarly, sunitinib did not show any improvement in the entire cohort for either DFS (HR 0.89, 95% CI 0.67-1.19) or OS (HR 1.11, 95% CI 0.90-1.37). CONCLUSIONS: In this meta-analysis, antiangiogenics did not improve OS and DFS over placebo in high-risk RCC after nephrectomy. Further studies are needed to identify the patient population that might derive a benefit from antiangiogenics in the adjuvant setting. PATIENT SUMMARY: In this article, we found that there is currently insufficient evidence to support the use of oral antiangiogenics in nonmetastatic renal cell carcinoma after nephrectomy. In addition, the use of oral antiangiogenics was associated with a 2.7-fold higher rate of significant side effects compared to placebo.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Sonbol MB, Firwana B, Hilal T, et al. Adjuvant Antiangiogenic Agents in Post-nephrectomy Renal Cell Carcinoma: A Systematic Review and Meta-analysis. Eur Urol Oncol. 2018. PMID: 30345423. doi:10.1016/j.euo.2018.03.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。